Abstract
To study the antioxidant profile of blood plasma in patients with paranoid schizophrenia and Alzheimer disease (AD). Thirty-three patients with paranoid schizophrenia and 18 patients with AD were included in the study. Patients with schizophrenia were stratified into two subgroups by response to therapy. The indicators of the antioxidant profile were determined using methods based on chemiluminometry and spectrofluorimetry. Systemic oxidative stress due to insufficiency of low molecular weight plasma antioxidants is not determined neither in AD nor in treatment resistant schizophrenia. At the same time, a «thiol» oxidative stress, which indirectly indicates a deficiency of the glutathione system, is present in both groups. In patients with paranoid schizophrenia responsive to treatment, systemic oxidative stress is more pronounced and «thiol» oxidative stress is less significant. Among the antipsychotics studied, haloperidol, zuclopenthixol, risperidone and ziprasidone do not exhibit antioxidant properties, but periciazine, clozapine and especially chlorpromazine exhibit strong antioxidant properties, but they unlikely affect the antioxidant potential of blood plasma. The glutathione part of the antioxidant system is mostly aff...Continue Reading
References
Sep 4, 1998·Psychiatry Research·J K YaoD P van Kammen
Jul 20, 2002·Peptides·D Allan Butterfield, Jaroslaw Kanski
Jul 13, 2004·Annals of the New York Academy of Sciences·Honglei LiuRui-Ming Liu
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Oct 4, 2007·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Gianfranco SpallettaPaola Bossù
Apr 27, 2010·Indian Journal of Dermatology·M EskandaniS Hasannia
Jun 22, 2010·Neuroscience Letters·Manuela PadurariuCristinel Stefanescu
Aug 18, 2010·Antioxidants & Redox Signaling·Daisuke Matsuzawa, Kenji Hashimoto
Sep 8, 2010·Rejuvenation Research·Cristiano CapursoVincenzo Solfrizzi
Dec 4, 2010·Antioxidants & Redox Signaling·Jeffrey K Yao, Matcheri S Keshavan
Jan 13, 2011·CNS & Neurological Disorders Drug Targets·Hector H PalaciosGjumrakch Aliev
Mar 12, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Xue Feng LiXiang Yang Zhang
Oct 22, 2011·Biochimica Et Biophysica Acta·Chava B Pocernich, D Allan Butterfield
Nov 29, 2011·Biochemical and Biophysical Research Communications·Pravat K MandalSreedevi Sugunan
Feb 14, 2012·Free Radical Biology & Medicine·Mariagioia ZampagniCristina Cecchi
Apr 13, 2012·Molecular Neurodegeneration·Mariet AllenNilüfer Ertekin-Taner
May 5, 2012·Schizophrenia Research·Xiang Yang ZhangThomas R Kosten
Jun 16, 2012·Journal of Alzheimer's Disease : JAD·Christopher ExleyMargaret M Esiri
Aug 14, 2012·Psychiatry Research·Fátima Ruiz-LitagoAna María González-Pinto
Feb 6, 2016·The Cochrane Database of Systematic Reviews·Pedro V S MagalhãesFlávio Kapczinski
Jul 28, 2016·Schizophrenia Research·Izabela Sadowska-BartoszAnna Dietrich-Muszalska
Sep 9, 2016·Physiological Reports·Andrew M RobertsEvelyne Gozal
Jun 10, 2017·Current Topics in Medicinal Chemistry·Giulia NesiSimona Rapposelli
Sep 12, 2017·The Australian and New Zealand Journal of Psychiatry·Yiru ZhangCynthia Shannon Weickert
Aug 21, 2018·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tushar Kanti DasLena Palaniyappan
Sep 19, 2018·Bratislavské lekárske listy·M Pohanka
Oct 3, 2018·Psychiatry Research·Čedo D MiljevićMihajlo B Spasić
Jul 30, 2019·Cognitive Neurodynamics·Ting XieYunlong Tan